XML 25 R11.htm IDEA: XBRL DOCUMENT

4. Intangible Assets, Goodwill and Other

12 Months Ended

Dec. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure

4. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):



	2016									2015
	Life Science			Clinical Diagnostics			Total			Life Science			Clinical Diagnostics			Total
Balances as of January 1:
Goodwill	$	207.2		$	316.9		$	524.1		$	207.7		$	320.9		$	528.6
Accumulated impairment losses and write-offs	(27.2		)	(1.0		)	(28.2		)	(27.2		)	(1.0		)	(28.2		)
Goodwill, net	180.0			315.9			495.9			180.5			319.9			500.4
Acquisitions	0.1			—			0.1			—			—			—
Impairment	—			(13.5		)	(13.5		)	—			—			—
Currency fluctuations	(0.2		)	(5.2		)	(5.4		)	(0.5		)	(4.0		)	(4.5		)
Balances as of December 31:
Goodwill	207.1			311.7			518.8			207.2			316.9			524.1
Accumulated impairment losses and write-offs	(27.2		)	(14.5		)	(41.7		)	(27.2		)	(1.0		)	(28.2		)
Goodwill, net	$	179.9		$	297.2		$	477.1		$	180.0		$	315.9		$	495.9

In conjunction with the purchase of certain assets from Propel in January 2016 (see Note 2, "Acquisitions"), we recorded $0.1 million of goodwill and $32.7 million of definite-lived intangible assets: $29.7 million of developed product technology and $3.0 million of covenants not to compete, after the effects of a calculation revision that were reflected in the fourth quarter of 2016.

Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):



	December 31, 2016
	Average Remaining Life (years)	Purchase Price		Accumulated Amortization			Net Carrying Amount
Customer relationships/lists	1-8	$	84.4	$	(52.8	)	$	31.6
Know how	1-9	182.6		(136.9		)	45.7
Developed product technology	3-12	125.9		(56.3		)	69.6
Licenses	1-9	39.0		(30.6		)	8.4
Tradenames	4-8	3.5		(2.5		)	1.0
Covenants not to compete	2-9	7.8		(2.5		)	5.3
Total definite-lived intangible assets		443.2		(281.6		)	161.6
In-process research and development		—		—			—
Total purchased intangible assets		$	443.2	$	(281.6	)	$	161.6



	December 31, 2015
	Average Remaining Life (years)	Purchase Price		Accumulated Amortization			Net Carrying Amount
Customer relationships/lists	2-10	$	84.7	$	(46.8	)	$	37.9
Know how	1-10	184.0		(121.6		)	62.4
Developed product technology	4-12	101.3		(48.9		)	52.4
Licenses	3-10	39.2		(28.5		)	10.7
Tradenames	5-9	3.5		(2.4		)	1.1
Covenants not to compete	3-7	4.8		(1.7		)	3.1
Total definite-lived intangible assets		417.5		(249.9		)	167.6
In-process research and development		46.4		—			46.4
Total purchased intangible assets		$	463.9	$	(249.9	)	$	214.0

In 2016, we fully impaired goodwill and in-process research and development in the amounts of $13.5 million and $46.4 million, respectively, associated with our 2014 acquisition of GnuBIO, Inc. The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows. There were no impairment losses recorded in 2015.

Amortization expense related to purchased intangible assets for the years ended December 31, 2016, 2015 and 2014 was $35.2 million, $36.5 million and $47.8 million, respectively. Estimated future amortization expense (based on existing purchased intangible assets) for the years ending December 31, 2017, 2018, 2019, 2020, 2021 and thereafter is $27.2 million, $24.2 million, $21.4 million, $19.4 million, $18.4 million, and $51.0 million, respectively.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details